Davis Polk advised the joint book-running managers in connection with the $112.5 million public offering of common stock of Achaogen, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “AKAO.”

Based in South San Francisco, California, Achaogen, Inc. is a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant gram-negative infections.

The Davis Polk corporate team included partner Bruce K. Dallas and associates Jeffrey C. Lau and Leeann Saw. The tax team included partner Rachel D. Kleinberg and associate Yoojin L. Kim. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post